Trial document
DRKS00010285
Trial Description
Title
(1,3)-β-D-glucan based diagnosis of invasive candida infection versus culture based diagnosis in patients with severe sepsis or septic shock and a high risk for invasive candida infection.
Trial Acronym
CandiSep
URL of the Trial
[---]*
Brief Summary in Lay Language
Critically ill patients with severe infections are in need of a broad antibiotic therapy. However, severe fungal infections are rather rare and should only be treaded if proven. Proof of fungal infections takes several day - time which is lost for adequate treatment. An untreated fungal infection is a high risk for critically ill patients. (1,3)-β-D-glucan (BDG) is part of many fungi and appears fast in the blood of infected patients. Several studies already used measurement of BDG to diagnose severe fungal infections. However, it is controversial whether this test works on an intensive care unit. This study investigates whether BDG measurements in critically ill patients facilitates an early antifungal therapy.
Brief Summary in Scientific Language
(1,3)-β-D-glucan is a component of the cell wall of many fungi including candida spp. and is present in the blood of patients with invasive candida infection (ICI). Several studies showed a good diagnostic accuracy (1,3)-β-D-glucan in predicting ICI. However, others have challenged (1,3)-β-D-glucan as a diagnostic tool in critically ill patients as many substances used in the intensive care unit might affect the results of the assay. The goal of this study is to investigate whether (1,3)-β-D-glucan can early identify sepsis patients in need of antifungal therapy. Patients randomized to the standard of care group receive antifungals depending on microbiological results according to current guidelines. Patients randomized to the BDG group receive antifungals depending on the (1,3)-β-D-glucan plasma concentration on day 1 and day after diagnosing sepsis. Therapy may be modified according to microbiological results.
Organizational Data
- DRKS00010285
- 2016/08/22
- 2016/04/06
- yes
- Approved
- 4754-04/16, Ethikkommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät
Secondary IDs
- U1111-1181-8724
- NCT02734550 (Clinicaltrials.gov)
Health Condition or Problem studied
- A41 - Other sepsis
- Severe sepsis, septic shock
Interventions/Observational Groups
- Standard of care: Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
- (1,3)-β-D-glucan guided therapy: In addition to standard care, serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile bod fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Open (masking not used)
- [---]*
- Active control (effective treament of control group)
- Diagnostic
- Parallel
- N/A
- N/A
Primary Outcome
28-day mortality
Secondary Outcome
28-day antifungal free survival, candida colonization, time to antifungal therapy, duration of organ support, 14 days mean total SOFA score, ICU und hospital length of stay, ICU ans hospital survival, adverse events, diagnostic accuracy of (1,3)-β-D-glucan in comparison to candida PCR and other experimental diagnostics, paracoeconomic analyses
Countries of Recruitment
- Germany
Locations of Recruitment
- Medical Center
- Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
- Medical Center
- University Medical Center
- Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
Recruitment
- Actual
- 2016/09/13
- 312
- Multicenter trial
- National
Inclusion Criteria
- Both, male and female
- 18 Years
- no maximum age
Additional Inclusion Criteria
Severe sepsis or septic shock
Increased risk for invasive candida infection (at least one of the following):
> total parenteral nutrition ≥48 hours
> abdominal surgery within the last 7 days
> antimicrobial therapy for at least 48 hours within the last 7 days
> Acute or chronic renal failure with renal replacement therapy
Onset of sepsis no longer than 24 hours
Age ≥18 years
Informed consent of the patient or legal representative or delayed consent process is started if patient is incapable of giving informed consent and no legal representative is available.
Exclusion Criteria
Pregnant or lactating women
Ongoing invasive candida infection
systemic antifungal therapy
liver cirrhosis Child C
cardiopulmonary bypass within the last 4 weeks
treatment with immunoglobulins within the last 14 days
immunosuppression (solid organ transplantation, AISA, leukopenia)
participation in another intervention study
no commitment to full therapy (i.e. DNR order)
Infauste Prognose aufgrund von Nebenerkrankungen
Kin to or colleague of study personnel
Addresses
-
start of 1:1-Block address primary-sponsor
- Friedrich-Schiller-Universität JenaMedizinische Fakultät
- Bachstr. 18
- 07743 Jena
- Germany
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- [---]*
- [---]*
- [---]*
- http://www.uni-jena.de/Medizinische_Fakultaet.html
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address scientific-contact
- Jena University Hospital Center for Sepsis Control & Care
- Mr. PD Dr. med. Frank Bloos
- Am Klinikum 1
- 07747 Jena
- Germany
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- +49-3641-9323283
- +49-3641-9323102
- frank.bloos at med.uni-jena.de
- http://www.cscc.uniklinikum-jena.de
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Jena University Hospital Center for Sepsis Control & Care
- Mr. PD Dr. med. Frank Bloos
- Am Klinikum 1
- 07747 Jena
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- +49-3641-9323283
- +49-3641-9323102
- frank.bloos at med.uni-jena.de
- [---]*
end of 1:1-Block address contact public-contact -
start of 1:1-Block address public-contact
- Jena University HospitalCenter for Sepsis Control & Care (CSCC)
- Mr. Daniel Thomas-Rüddel
- Am Klinikum 1
- 07747 Jena
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- +49-3641-9323267
- +49-3641-9323102
- daniel.thomas at med.uni-jena.de
- http://www.cscc.uniklinikum-jena.de
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Bundesministerium für Bildung und Forschung Dienstsitz Berlin
- Friedrichstraße 130 B
- 10117 Berlin
- Germany
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- http://www.bmbf.de
end of 1:1-Block address contact materialSupport -
start of 1:1-Block address otherSupport
- Associates of Cape Cod, Inc.
- Mr. Dr. Malcolm Finkelman
- 124 Bernard St. Jean Drive
- 02536 East Falmouth
- United States
end of 1:1-Block address otherSupportstart of 1:1-Block address contact otherSupport- [---]*
- [---]*
- mfinkelman at acciusa.com
- [---]*
end of 1:1-Block address contact otherSupport
Status
- Recruiting complete, follow-up continuing
- [---]*
Trial Publications, Results and other Documents
- [---]*